ATEC Announces Select Preliminary Financial Results for 2024 and Provides 2025 Outlook
Alphatec Holdings (ATEC) reported preliminary financial results for 2024 and provided outlook for 2025. The company achieved 27% growth in total revenue to approximately $611 million for full-year 2024. Surgical revenue showed strong performance with 29% growth, driven by 19% surgical volume growth and 8% increase in average revenue per procedure.
The company's cash balance reached $139 million as of December 31, 2024, representing a $58 million increase from Q3 2024, including $50 million from a term loan expansion. For 2025, ATEC projects total revenue of $732 million, indicating approximately 20% growth, with surgical revenue expected at $657 million and EOS revenue at $75 million. The company also anticipates adjusted EBITDA of about $75 million and expects to achieve positive free cash flow in 2025.
Alphatec Holdings (ATEC) ha riportato risultati finanziari preliminari per il 2024 e ha fornito le prospettive per il 2025. L'azienda ha raggiunto una crescita del 27% nel fatturato totale, arrivando a circa 611 milioni di dollari per l'intero anno 2024. Il fatturato chirurgico ha mostrato una forte performance con una crescita del 29%, sostenuta da una crescita del volume chirurgico del 19% e un incremento dell'8% del fatturato medio per procedura.
Il saldo di cassa dell'azienda ha raggiunto 139 milioni di dollari al 31 dicembre 2024, rappresentando un aumento di 58 milioni di dollari rispetto al terzo trimestre del 2024, inclusi 50 milioni di dollari provenienti da un'espansione di un prestito a termine. Per il 2025, ATEC prevede un fatturato totale di 732 milioni di dollari, indicando una crescita di circa il 20%, con un fatturato chirurgico atteso di 657 milioni di dollari e un fatturato EOS di 75 milioni di dollari. L'azienda prevede anche un EBITDA rettificato di circa 75 milioni di dollari e si aspetta di raggiungere un flusso di cassa libero positivo nel 2025.
Alphatec Holdings (ATEC) informó resultados financieros preliminares para 2024 y proporcionó perspectivas para 2025. La compañía logró un crecimiento del 27% en los ingresos totales, alcanzando aproximadamente 611 millones de dólares para el año completo 2024. Los ingresos quirúrgicos mostraron un rendimiento sólido con un crecimiento del 29%, impulsado por un crecimiento del volumen quirúrgico del 19% y un aumento del 8% en los ingresos promedio por procedimiento.
El saldo de efectivo de la compañía alcanzó 139 millones de dólares al 31 de diciembre de 2024, representando un aumento de 58 millones de dólares desde el tercer trimestre de 2024, incluyendo 50 millones de dólares de una expansión de préstamo a plazo. Para 2025, ATEC proyecta ingresos totales de 732 millones de dólares, indicando un crecimiento de aproximadamente el 20%, con ingresos quirúrgicos esperados de 657 millones de dólares y ingresos de EOS de 75 millones de dólares. La compañía también anticipa un EBITDA ajustado de alrededor de 75 millones de dólares y espera alcanzar un flujo de efectivo libre positivo en 2025.
알파텍 홀딩스 (ATEC)는 2024년의 예비 재무 결과를 보고하고 2025년 전망을 제공했습니다. 이 회사는 2024년 전체 연도 동안 약 6억 11백만 달러에 달하는 총 수익에서 27% 성장을 달성했습니다. 외과 수익은 외과적 볼륨 19% 증가와 절차당 평균 수익 8% 증가에 의해 주도된 29% 성장으로 강력한 성능을 보였습니다.
회사의 현금 잔고는 2024년 12월 31일 기준 1억 3900만 달러에 도달했으며, 이는 2024년 3분기 대비 5800만 달러 증가한 금액으로, 5000만 달러의 만기 대출 확장을 포함하고 있습니다. 2025년을 위해 ATEC는 총 수익을 7억 3200만 달러로 예상하며, 이는 약 20% 성장하는 것을 나타내며, 외과 수익은 6억 5700만 달러, EOS 수익은 7500만 달러로 기대되고 있습니다. 회사는 또한 약 7500만 달러의 조정된 EBITDA를 예상하고 있으며 2025년에는 긍정적인 자유 현금 흐름을 달성할 것으로 기대하고 있습니다.
Alphatec Holdings (ATEC) a rapporté des résultats financiers préliminaires pour 2024 et a fourni des perspectives pour 2025. La société a réalisé une croissance de 27% de son chiffre d'affaires total, atteignant environ 611 millions de dollars pour l'année entière 2024. Les revenus chirurgicaux ont affiché une solide performance avec une croissance de 29%, soutenue par une croissance du volume chirurgical de 19% et une augmentation de 8% du revenu moyen par intervention.
Le solde de la trésorerie de l'entreprise a atteint 139 millions de dollars au 31 décembre 2024, représentant une augmentation de 58 millions de dollars par rapport au troisième trimestre 2024, y compris 50 millions de dollars provenant d'une expansion de prêt à terme. Pour 2025, ATEC prévoit un chiffre d'affaires total de 732 millions de dollars, indiquant une croissance d'environ 20%, avec des revenus chirurgicaux prévus à 657 millions de dollars et des revenus EOS à 75 millions de dollars. L'entreprise anticipe également un EBITDA ajusté d'environ 75 millions de dollars et s'attend à atteindre un flux de trésorerie libre positif en 2025.
Alphatec Holdings (ATEC) hat vorläufige Finanzzahlen für 2024 berichtet und einen Ausblick für 2025 gegeben. Das Unternehmen erzielte ein Wachstum von 27% beim Gesamterlös und erreichte etwa 611 Millionen Dollar für das Gesamtjahr 2024. Die Einnahmen aus chirurgischen Eingriffen zeigten eine starke Leistung mit einem Wachstum von 29%, angetrieben durch ein Wachstum des chirurgischen Volumens von 19% und einen Anstieg von 8% beim durchschnittlichen Erlös pro Eingriff.
Der Bargeldbestand des Unternehmens belief sich zum 31. Dezember 2024 auf 139 Millionen Dollar, was einem Anstieg von 58 Millionen Dollar im Vergleich zum dritten Quartal 2024 entspricht, einschließlich 50 Millionen Dollar aus einer Erweiterung eines Terminkredits. Für 2025 rechnet ATEC mit einem Gesamtumsatz von 732 Millionen Dollar, was einem Wachstum von etwa 20% entspricht, wobei die chirurgischen Einnahmen voraussichtlich 657 Millionen Dollar und die EOS-Einnahmen 75 Millionen Dollar betragen werden. Das Unternehmen erwartet auch ein bereinigtes EBITDA von etwa 75 Millionen Dollar und rechnet damit, 2025 einen positiven freien Cashflow zu erzielen.
- 27% total revenue growth to $611M in 2024
- 29% surgical revenue growth with 19% volume increase
- Cash balance increased by $58M to $139M in Q4 2024
- Projected 20% revenue growth to $732M for 2025
- Expected positive free cash flow and $75M adjusted EBITDA in 2025
- None.
Insights
ATEC's preliminary 2024 results and 2025 outlook showcase remarkable financial momentum. The 27% revenue growth to
The 2025 projection of
The surgical revenue target of
The spine surgery market dynamics strongly favor ATEC's positioning. Their focus on surgical predictability and informatics integration creates significant barriers to entry. The 19% surgical volume growth significantly outpaces the industry average of 3-4%, indicating substantial market share capture from established players.
The company's "distinction-driven demand" strategy is yielding results through their 100% spine-focused approach. This specialization allows for deeper market penetration and stronger surgeon relationships, evidenced by the robust procedure volume growth. The integration of informatics into surgical approaches represents a strategic moat, particularly valuable as healthcare increasingly emphasizes data-driven decision-making.
ATEC's technological differentiation is driving exceptional adoption metrics. The combination of surgical volume growth and revenue per procedure expansion indicates successful implementation of advanced surgical solutions. The EOS imaging segment, projected at
The focus on informatics integration is particularly noteworthy as it aligns with the broader healthcare trend toward data-driven surgical decision support. This approach not only improves surgical outcomes but also creates recurring revenue opportunities through software and analytics services, potentially leading to margin expansion over time.
-
Full-year 2024 total revenue grew
27% to approximately$611 million -
Expect full-year 2025 total revenue of
$732 million
Preliminary, Unaudited Fourth Quarter and Full-Year 2024 Revenue Ranges
|
Fourth Quarter Ended December 31, 2024 |
Full-Year Ended December 31, 2024 |
||
Surgical Revenue |
|
|
||
EOS Revenue |
|
|
||
Total Revenue |
|
|
||
May not foot due to rounding |
|
Preliminary total revenue grew approximately
Preliminary, Unaudited Year-End 2024 Cash Balance
Cash balance as of December 31, 2024, approximated
“Our dedication to revolutionizing spine surgery fueled another year of sector-leading growth and an inflection to profitability in 2024,” said Pat Miles, Chairman and Chief Executive Officer. “As we look to what is ahead, we know our best is yet to come. ATEC is uniquely applying
The preliminary revenue results announced today are based on the Company’s current expectations and may be adjusted as a result of, among other things, completion of customary annual audit procedures.
Financial Outlook for the Full-Year 2025
The Company anticipates full-year 2025 total revenue of
The Company will report fourth quarter and full-year 2024 financial results on February 26, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET.
Webcast
To access the live webcast or a replay of the webcast, please visit the Investor Relations Section of ATEC’s Corporate Website.
Dial-in
To dial into the live webcast, please register at this link. Access details will be shared via email.
Inducement Awards Granted
As an inducement material to accepting employment with the Company, and in accordance with Nasdaq Listing Rule 5635(c)(4), ATEC today announced that the independent Compensation Committee of the Board of Directors has approved aggregate grants to 12 new employees (who are not executive officers) of, collectively, 26,013 restricted stock units (“RSUs”) under the Company’s 2016 Employment Inducement Award Plan. The RSUs will vest in equal annual installments on each of the first four anniversaries of the grant date, provided that the recipient remains continuously employed by ATEC as of such vesting date. In addition, the RSUs will vest fully upon a change of control of ATEC.
Non-GAAP Financial Information
To supplement the Company’s financial statements presented in accordance with generally accepted accounting principles in
About ATEC
ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation Machine™ is focused on developing new approaches that integrate seamlessly with the Company’s expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC’s vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described therein. Forward-looking statements include references to the Company’s expectations with respect to future revenue, growth, free cash flow, financial outlook, profitability, differentiated product portfolio and the ability to self-fund growth and drive demand. The important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: failure to achieve acceptance of the Company’s products by the surgeon community and changes to our financial results for the quarter and year ended December 31, 2024 due to the completion of financial closing procedures. The words “believe,” “will,” “should,” “expect,” “intend,” “estimate,” “look forward” and “anticipate,” and variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113674305/en/
Investor/Media Contact:
Tina Jacobsen, CFA
Investor Relations
(760) 494-6790
investorrelations@atecspine.com
Company Contact:
J. Todd Koning
Chief Financial Officer
Alphatec Holdings, Inc.
investorrelations@atecspine.com
Source: Alphatec Holdings, Inc.
FAQ
What was ATEC's total revenue growth for full-year 2024?
How much did ATEC's surgical revenue grow in 2024?
What is ATEC's revenue forecast for 2025?
What was ATEC's cash balance at the end of 2024?
What are ATEC's EBITDA and cash flow projections for 2025?
